Moonwalk Biosciences discloses $70.2 million equity offering in SEC Form D
The South San Francisco biotech has sold nearly $60 million of a planned $70.2 million round to seven investors, according to a filing dated September 14, 2026.
Moonwalk Biosciences, Inc. filed a Form D with the Securities and Exchange Commission disclosing an exempt securities offering. The filing lists a total offering amount of $70,249,973, with $59,999,998 already sold and $10,249,975 remaining to be sold1.
The company reported a total of seven investors who have already invested in the offering1. The filing states a date of first sale of 2026-08-261, and was signed on 2026-09-14 by Arash Jamshidi, President1.
Moonwalk Biosciences is headquartered at 2 Tower Place, 8th Floor, South San Francisco, California, 940801, and is incorporated in Delaware, organized in 20221. The company classifies itself under the Health Care industry group, specifically Biotechnology1.
The offering was made under Rule 506(b)1 of Regulation D, and the company indicated it does not intend the offering to last more than one year1. The filing states the offering is an equity offering not made in connection with a business combination transaction such as a merger, acquisition or exchange offer1.
Regarding minimum investment amounts, the filing lists a minimum investment accepted from any outside investor of $01. No sales commissions or finder's fees were reported, with the filing showing $0 in sales commissions and $0 in finders' fees1. Similarly, the company reported $0 of gross proceeds designated for payments to executive officers, directors or promoters1.
The related persons listed in the filing include Alexander Aravanis and Arash Jamshidi, both identified as Executive Officer and Director1, along with several other officers and directors named in the same filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.